Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Operating Expenses (2021 - 2025)

Prime Medicine's Operating Expenses history spans 5 years, with the latest figure at $49.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 6.55% year-over-year to $49.4 million; the TTM value through Dec 2025 reached $213.0 million, up 3.67%, while the annual FY2025 figure was $213.0 million, 3.67% up from the prior year.
  • Operating Expenses reached $49.4 million in Q4 2025 per PRME's latest filing, down from $55.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $68.0 million in Q4 2023 to a low of $10.4 million in Q3 2021.
  • Average Operating Expenses over 5 years is $45.0 million, with a median of $49.2 million recorded in 2024.
  • The largest YoY upside for Operating Expenses was 203.59% in 2022 against a maximum downside of 35.6% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $60.1 million in 2021, then plummeted by 35.6% to $38.7 million in 2022, then skyrocketed by 75.89% to $68.0 million in 2023, then tumbled by 31.8% to $46.4 million in 2024, then rose by 6.55% to $49.4 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Operating Expenses are $49.4 million (Q4 2025), $55.2 million (Q3 2025), and $54.5 million (Q2 2025).